List view / Grid view

Eli Lilly & Company

 

news

New Phase 3 data for Tradjenta® (linagliptin) tablets

24 May 2012 | By Eli Lilly and Company

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Phase 3 study results for linagliptin 5 mg once-daily, which showed significant hemoglobin A1c (HbA1c or A1C) reduction of 0.88 percent compared to 0.24 percent in the placebo group (p=0.0002) at 24 weeks in black or African…